Christine E Seidman

List of Publications by Year in Descending Order

207 papers	24,364 citations	73 h-index	155 g-index
224 ext. papers	29,468 ext. citations	16.4 avg, IF	6.3 L-index

#	Paper	IF	Citations
207	Genetic determinants of telomere length from 109,122 ancestrally diverse whole-genome sequences in TOPMed.. *Cell Genomics*, **2022**, 2, 100084-100084		1
206	Cell cycle defects underlie childhood-onset cardiomyopathy associated with Noonan syndrome.. *IScience*, **2022**, 25, 103596	6.1	0
205	Genome-Wide De Novo Variants in Congenital Heart Disease Are Not Associated With Maternal Diabetes or Obesity.. *Circulation Genomic and Precision Medicine*, **2022**, CIRCGEN121003500	5.2	0
204	Transcription factor protein interactomes reveal genetic determinants in heart disease.. *Cell*, **2022**,	56.2	3
203	Neither cardiac mitochondrial DNA variation or copy number contribute to congenital heart disease risk.. *American Journal of Human Genetics*, **2022**,	11	1
202	Genetics of cancer therapy-associated cardiotoxicity.. *Journal of Molecular and Cellular Cardiology*, **2022**,	5.8	2
201	Engineering a living cardiac pump on a chip using high-precision fabrication.. *Science Advances*, **2022**, 8, eabm3791	14.3	4
200	Population Prevalence of Premature Truncating Variants in Plakophilin-2 and Association With Arrhythmogenic Right Ventricular Cardiomyopathy: a UK Biobank Analysis.. *Circulation Genomic and Precision Medicine*, **2022**, 101161CIRCGEN121003507	5.2	0
199	An ancient founder mutation located between and is responsible for increased microtia risk in Amerindigenous populations.. *Proceedings of the National Academy of Sciences of the United States of America*, **2022**, 119, e2203928119	11.5	0
198	Associations Between Female Sex, Sarcomere Variants, and Clinical Outcomes in Hypertrophic Cardiomyopathy. *Circulation Genomic and Precision Medicine*, **2021**, 14, e003062	5.2	10
197	Targeted therapies in genetic dilated and hypertrophic cardiomyopathies: From molecular mechanisms to therapeutic targets.. *European Journal of Heart Failure*, **2021**,	12.3	2
196	Plakophilin-2 truncating variants impair cardiac contractility by disrupting sarcomere stability and organization. *Science Advances*, **2021**, 7, eabh3995	14.3	1
195	Mechanisms of Congenital Heart Disease Caused by NAA15 Haploinsufficiency. *Circulation Research*, **2021**, 128, 1156-1169	15.7	2
194	Genetic and Phenotypic Landscape of Peripartum Cardiomyopathy. *Circulation*, **2021**, 143, 1852-1862	16.7	11
193	Isolation of Nuclei from Mammalian Cells and Tissues for Single-Nucleus Molecular Profiling. *Current Protocols*, **2021**, 1, e132		4
192	Cardiomyocyte Proliferative Capacity Is Restricted in Mice With Mutation. *Frontiers in Cardiovascular Medicine*, **2021**, 8, 639148	5.4	3
191	CalTrack: High-Throughput Automated Calcium Transient Analysis in Cardiomyocytes. *Circulation Research*, **2021**, 129, 326-341	15.7	8

190	Association of Damaging Variants in Genes With Increased Cancer Risk Among Patients With Congenital Heart Disease. *JAMA Cardiology*, **2021**, 6, 457-462	16.2	12
189	Modeling Human TBX5 Haploinsufficiency Predicts Regulatory Networks for Congenital Heart Disease. *Developmental Cell*, **2021**, 56, 292-309.e9	10.2	17
188	Probing the subcellular nanostructure of engineered human cardiomyocytes in 3D tissue. *Microsystems and Nanoengineering*, **2021**, 7, 10	7.7	1
187	Discordant clinical features of identical hypertrophic cardiomyopathy twins. *Proceedings of the National Academy of Sciences of the United States of America*, **2021**, 118,	11.5	5
186	Genomic frontiers in congenital heart disease. *Nature Reviews Cardiology*, **2021**,	14.8	15
185	Contribution of Noncanonical Splice Variants to Truncating Variant Cardiomyopathy. *Circulation Genomic and Precision Medicine*, **2021**, 14, e003389	5.2	0
184	Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trial. *Nature Medicine*, **2021**, 27, 1818-1824	50.5	7
183	Filamin C Cardiomyopathy Variants Cause Protein and Lysosome Accumulation. *Circulation Research* , **2021**, 129, 751-766	15.7	2
182	Systems Analysis Implicates WAVE2 Complex in the Pathogenesis of Developmental Left-Sided Obstructive Heart Defects. *JACC Basic To Translational Science*, **2020**, 5, 376-386	8.7	2
181	Complement genes contribute sex-biased vulnerability in diverse disorders. *Nature*, **2020**, 582, 577-581	50.4	71
180	Congenital Heart Defects Due to Missense Variants. *Circulation Genomic and Precision Medicine*, **2020**, 13, e002843	5.2	3
179	Expanding the clinical and genetic spectrum of ALPK3 variants: Phenotypes identified in pediatric cardiomyopathy patients and adults with heterozygous variants. *American Heart Journal*, **2020**, 225, 108-119	4.9	7
178	Hypertrophic cardiomyopathy in myosin-binding protein C () Icelandic founder mutation carriers. *Open Heart*, **2020**, 7, e001220	3	2
177	Genomic analyses implicate noncoding de novo variants in congenital heart disease. *Nature Genetics*, **2020**, 52, 769-777	36.3	33
176	De Novo Damaging Variants, Clinical Phenotypes, and Post-Operative Outcomes in Congenital Heart Disease. *Circulation Genomic and Precision Medicine*, **2020**, 13, e002836	5.2	15
175	Myosin Sequestration Regulates Sarcomere Function, Cardiomyocyte Energetics, and Metabolism, Informing the Pathogenesis of Hypertrophic Cardiomyopathy. *Circulation*, **2020**, 141, 828-842	16.7	66
174	EM-mosaic detects mosaic point mutations that contribute to congenital heart disease. *Genome Medicine*, **2020**, 12, 42	14.4	8
173	BET bromodomain proteins regulate transcriptional reprogramming in genetic dilated cardiomyopathy. *JCI Insight*, **2020**, 5,	9.9	12

172	Rare genetic variation at transcription factor binding sites modulates local DNA methylation profiles. *PLoS Genetics*, **2020**, 16, e1009189	6	7
171	mutations in hiPSCs inform mechanisms for maldevelopment of the heart, pancreas, and diaphragm. *ELife*, **2020**, 9,	8.9	9
170	Marked Up-Regulation of ACE2 in Hearts of Patients With Obstructive Hypertrophic Cardiomyopathy: Implications for SARS-CoV-2-Mediated COVID-19. *Mayo Clinic Proceedings*, **2020**, 95, 1354-1368	6.4	31
169	Genetic Cardiomyopathies **2020**, 77-114		1
168	Scientists on the Spot: Putting a halt to hypertrophic cardiomyopathy. *Cardiovascular Research*, **2020**, 116, e42-e43	9.9	
167	Association of Race With Disease Expression and Clinical Outcomes Among Patients With Hypertrophic Cardiomyopathy. *JAMA Cardiology*, **2020**, 5, 83-91	16.2	23
166	Cells of the adult human heart. *Nature*, **2020**, 588, 466-472	50.4	274
165	Founder Mutation in N Terminus of Cardiac Troponin I Causes Malignant Hypertrophic Cardiomyopathy. *Circulation Genomic and Precision Medicine*, **2020**, 13, 444-452	5.2	3
164	Genetic Studies of Hypertrophic Cardiomyopathy in Singaporeans Identify Variants in and That Are Common in Chinese Patients. *Circulation Genomic and Precision Medicine*, **2020**, 13, 424-434	5.2	4
163	Abnormal Left-Hemispheric Sulcal Patterns Correlate with Neurodevelopmental Outcomes in Subjects with Single Ventricular Congenital Heart Disease. *Cerebral Cortex*, **2020**, 30, 476-487	5.1	11
162	Yin Yang 1 Suppresses Dilated Cardiomyopathy and Cardiac Fibrosis Through Regulation of and. *Circulation Research*, **2019**, 125, 834-846	15.7	20
161	SarcTrack. *Circulation Research*, **2019**, 124, 1172-1183	15.7	56
160	Hypertrophic cardiomyopathy mutations in dysregulate myosin. *Science Translational Medicine*, **2019**, 11,	17.5	73
159	Novel Therapies for Prevention and Early Treatment of Cardiomyopathies. *Circulation Research*, **2019**, 124, 1536-1550	15.7	22
158	Histone H2B monoubiquitination regulates heart development via epigenetic control of cilia motility. *Proceedings of the National Academy of Sciences of the United States of America*, **2019**, 116, 14049-14054	11.5	17
157	The Translational Landscape of the Human Heart. *Cell*, **2019**, 178, 242-260.e29	56.2	210
156	Genetic Variants Associated With Cancer Therapy-Induced Cardiomyopathy. *Circulation*, **2019**, 140, 31-41	16.7	110
155	Response by Ho et al to Letter Regarding Article, "Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights From the Sarcomeric Human Cardiomyopathy Registry (SHaRe)". *Circulation*, **2019**, 139, 1559-1560	16.7	2

154	Activin type II receptor signaling in cardiac aging and heart failure. *Science Translational Medicine*, **2019**, 11,	17.5	43
153	Advances in the Genetic Basis and Pathogenesis of Sarcomere Cardiomyopathies. *Annual Review of Genomics and Human Genetics*, **2019**, 20, 129-153	9.7	59
152	A gene-centric strategy for identifying disease-causing rare variants in dilated cardiomyopathy. *Genetics in Medicine*, **2019**, 21, 133-143	8.1	20
151	Genome sequencing as a first-line genetic test in familial dilated cardiomyopathy. *Genetics in Medicine*, **2019**, 21, 650-662	8.1	36
150	Paternal-age-related de novo mutations and risk for five disorders. *Nature Communications*, **2019**, 10, 3043	17.4	33
149	De novo and recessive forms of congenital heart disease have distinct genetic and phenotypic landscapes. *Nature Communications*, **2019**, 10, 4722	17.4	25
148	The uptake of family screening in hypertrophic cardiomyopathy and an online video intervention to facilitate family communication. *Molecular Genetics & Genomic Medicine*, **2019**, 7, e940	2.3	5
147	Precision Medicine in the Management of Dilated Cardiomyopathy: JACC State-of-the-Art Review. *Journal of the American College of Cardiology*, **2019**, 74, 2921-2938	15.1	33
146	Genetic Testing and Counseling for Hypertrophic Cardiomyopathy. *Cardiology Clinics*, **2019**, 37, 35-43	2.5	8
145	Sex differences in gene expression in response to ischemia in the human left ventricular myocardium. *Human Molecular Genetics*, **2019**, 28, 1682-1693	5.6	18
144	Response to Brodehl et al. *Genetics in Medicine*, **2019**, 21, 1248-1249	8.1	
143	Human Induced Pluripotent Stem Cell Production and Expansion from Blood using a Non-Integrating Viral Reprogramming Vector. *Current Protocols in Molecular Biology*, **2018**, 122, e58	2.9	5
142	Robust identification of mosaic variants in congenital heart disease. *Human Genetics*, **2018**, 137, 183-193	6.3	26
141	CRISPR/Cas9-Mediated Fluorescent Tagging of Endogenous Proteins in Human Pluripotent Stem Cells. *Current Protocols in Human Genetics*, **2018**, 96, 21.11.1-21.11.20	3.2	30
140	Differentiation and Contractile Analysis of GFP-Sarcomere Reporter hiPSC-Cardiomyocytes. *Current Protocols in Human Genetics*, **2018**, 96, 21.12.1-21.12.12	3.2	18
139	Force Generation via β-Cardiac Myosin, Titin, and α-Actinin Drives Cardiac Sarcomere Assembly from Cell-Matrix Adhesions. *Developmental Cell*, **2018**, 44, 87-96.e5	10.2	75
138	Spatiotemporal Multi-Omics Mapping Generates a Molecular Atlas of the Aortic Valve and Reveals Networks Driving Disease. *Circulation*, **2018**, 138, 377-393	16.7	102
137	Genetic Pathogenesis of Hypertrophic and Dilated Cardiomyopathy. *Heart Failure Clinics*, **2018**, 14, 139-146	3.9	49

136	Robust identification of deletions in exome and genome sequence data based on clustering of Mendelian errors. *Human Mutation*, **2018**, 39, 870-881	4.7	1
135	Genetics of pediatric cardiomyopathies. *Progress in Pediatric Cardiology*, **2018**, 49, 18-19	0.4	2
134	An integrated clinical program and crowdsourcing strategy for genomic sequencing and Mendelian disease gene discovery. *Npj Genomic Medicine*, **2018**, 3, 21	6.2	15
133	Association of Variants in BAG3 With Cardiomyopathy Outcomes in African American Individuals. *JAMA Cardiology*, **2018**, 3, 929-938	16.2	30
132	ViroFind: A novel target-enrichment deep-sequencing platform reveals a complex JC virus population in the brain of PML patients. *PLoS ONE*, **2018**, 13, e0186945	3.7	16
131	In vivo and In vitro methods to identify DNA sequence variants that alter RNA Splicing. *Current Protocols in Human Genetics*, **2018**, 97, e60	3.2	2
130	Cardiac-enriched BAF chromatin-remodeling complex subunit Baf60c regulates gene expression programs essential for heart development and function. *Biology Open*, **2018**, 7,	2.2	19
129	Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe). *Circulation*, **2018**, 138, 1387-1398	16.7	210
128	Hierarchical and stage-specific regulation of murine cardiomyocyte maturation by serum response factor. *Nature Communications*, **2018**, 9, 3837	17.4	36
127	Multilayer Myocardial Mechanics in Genotype-Positive Left Ventricular Hypertrophy-Negative Patients With Hypertrophic Cardiomyopathy. *American Journal of Cardiology*, **2018**, 122, 1754-1760	3	11
126	Molecular Genetics of Lidocaine-Containing Cardioplegia in the Human Heart During Cardiac Surgery. *Annals of Thoracic Surgery*, **2018**, 106, 1379-1387	2.7	6
125	The Transcriptional Signature of Growth in Human Fetal Aortic Valve Development. *Annals of Thoracic Surgery*, **2018**, 106, 1834-1840	2.7	5
124	Telomere shortening is a hallmark of genetic cardiomyopathies. *Proceedings of the National Academy of Sciences of the United States of America*, **2018**, 115, 9276-9281	11.5	30
123	Dynamic Cellular Integration Drives Functional Assembly of the Heart's Pacemaker Complex. *Cell Reports*, **2018**, 23, 2283-2291	10.6	11
122	The Long Noncoding RNA Landscape of the Ischemic Human Left Ventricle. *Circulation: Cardiovascular Genetics*, **2017**, 10,		20
121	The Burden of Early Phenotypes and the Influence of Wall Thickness in Hypertrophic Cardiomyopathy Mutation Carriers: Findings From the HCMNet Study. *JAMA Cardiology*, **2017**, 2, 419-428	16.2	35
120	Macrophages Facilitate Electrical Conduction in the Heart. *Cell*, **2017**, 169, 510-522.e20	56.2	438
119	Cardiac Myosin Binding Protein-C Autoantibodies are Potential Early Indicators of Cardiac Dysfunction and Patient Outcome in Acute Coronary Syndrome. *JACC Basic To Translational Science*, **2017**, 2, 122-131	8.7	1

118	Bedside Back to Bench: Building Bridges between Basic and Clinical Genomic Research. *Cell*, **2017**, 169, 6-12	56.2	81
117	Early remodeling of repolarizing K currents in the MHC mouse model of familial hypertrophic cardiomyopathy. *Journal of Molecular and Cellular Cardiology*, **2017**, 103, 93-101	5.8	3
116	Cardiovascular homeostasis dependence on MICU2, a regulatory subunit of the mitochondrial calcium uniporter. *Proceedings of the National Academy of Sciences of the United States of America*, **2017**, 114, E9096-E9104	11.5	35
115	Contribution of rare inherited and de novo variants in 2,871 congenital heart disease probands. *Nature Genetics*, **2017**, 49, 1593-1601	36.3	348
114	A Comparison of Whole Genome Sequencing to Multigene Panel Testing in Hypertrophic Cardiomyopathy Patients. *Circulation: Cardiovascular Genetics*, **2017**, 10,		45
113	Joint analysis of left ventricular expression and circulating plasma levels of Omentin after myocardial ischemia. *Cardiovascular Diabetology*, **2017**, 16, 87	8.7	12
112	Fabry Disease in Families With Hypertrophic Cardiomyopathy: Clinical Manifestations in the Classic and Later-Onset Phenotypes. *Circulation: Cardiovascular Genetics*, **2017**, 10,		13
111	IL-11 is a crucial determinant of cardiovascular fibrosis. *Nature*, **2017**, 552, 110-115	50.4	267
110	Identification of pathogenic gene mutations in and that alter RNA splicing. *Proceedings of the National Academy of Sciences of the United States of America*, **2017**, 114, 7689-7694	11.5	42
109	Titin-truncating variants affect heart function in disease cohorts and the general population. *Nature Genetics*, **2017**, 49, 46-53	36.3	179
108	Effects of myosin variants on interacting-heads motif explain distinct hypertrophic and dilated cardiomyopathy phenotypes. *ELife*, **2017**, 6,	8.9	87
107	A Novel Role for in a Lebanese Family with Congenital Cardiac Defects. *Frontiers in Genetics*, **2017**, 8, 217	4.5	4
106	Detection of Cell Proliferation Markers by Immunofluorescence Staining and Microscopy Imaging in Paraffin-Embedded Tissue Sections. *Current Protocols in Molecular Biology*, **2016**, 115, 14.25.1-14.25.14	2.9	11
105	Aggregate penetrance of genomic variants for actionable disorders in European and African Americans. *Science Translational Medicine*, **2016**, 8, 364ra151	17.5	41
104	Single-Cell Resolution of Temporal Gene Expression during Heart Development. *Developmental Cell* , **2016**, 39, 480-490	10.2	231
103	Loss of RNA expression and allele-specific expression associated with congenital heart disease. *Nature Communications*, **2016**, 7, 12824	17.4	33
102	Pitx2 modulates a Tbx5-dependent gene regulatory network to maintain atrial rhythm. *Science Translational Medicine*, **2016**, 8, 354ra115	17.5	79
101	Preparation of rAAV9 to Overexpress or Knockdown Genes in Mouse Hearts. *Journal of Visualized Experiments*, **2016**,	1.6	4

100	Mutation analysis of the phospholamban gene in 315 South Africans with dilated, hypertrophic, peripartum and arrhythmogenic right ventricular cardiomyopathies. *Scientific Reports*, **2016**, 6, 22235	4.9	23
99	The Role of the L-Type Ca Channel in Altered Metabolic Activity in a Murine Model of Hypertrophic Cardiomyopathy. *JACC Basic To Translational Science*, **2016**, 1, 61-72	8.7	9
98	A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice. *Science*, **2016**, 351, 617-21	33.3	282
97	The Muscle-Bound Heart. *Cardiac Electrophysiology Clinics*, **2016**, 8, 223-31	1.4	3
96	Shared Genetic Predisposition in Peripartum and Dilated Cardiomyopathies. *New England Journal of Medicine*, **2016**, 374, 233-41	59.2	290
95	Molecular profiling of dilated cardiomyopathy that progresses to heart failure. *JCI Insight*, **2016**, 1,	9.9	55
94	THSD1 (Thrombospondin Type 1 Domain Containing Protein 1) Mutation in the Pathogenesis of Intracranial Aneurysm and Subarachnoid Hemorrhage. *Stroke*, **2016**, 47, 3005-3013	6.7	26
93	Integrative Analysis of PRKAG2 Cardiomyopathy iPS and Microtissue Models Identifies AMPK as a Regulator of Metabolism, Survival, and Fibrosis. *Cell Reports*, **2016**, 17, 3292-3304	10.6	51
92	Clinical and Mechanistic Insights Into the Genetics of Cardiomyopathy. *Journal of the American College of Cardiology*, **2016**, 68, 2871-2886	15.1	164
91	A Tension-Based Model Distinguishes Hypertrophic versus Dilated Cardiomyopathy. *Cell*, **2016**, 165, 1147-1159	36.1	122
90	Cardiac myosin binding protein C regulates postnatal myocyte cytokinesis. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, 9046-51	11.5	28
89	Integrated allelic, transcriptional, and phenomic dissection of the cardiac effects of titin truncations in health and disease. *Science Translational Medicine*, **2015**, 7, 270ra6	17.5	267
88	HEART DISEASE. Titin mutations in iPS cells define sarcomere insufficiency as a cause of dilated cardiomyopathy. *Science*, **2015**, 349, 982-6	33.3	379
87	Haploinsufficiency of MYBPC3 exacerbates the development of hypertrophic cardiomyopathy in heterozygous mice. *Journal of Molecular and Cellular Cardiology*, **2015**, 79, 234-43	5.8	41
86	163 Integrated allelic, transcriptional, and phenotypic dissection of the cardiac effects of titin variation in health and disease. *Heart*, **2015**, 101, A93.1-A93	5.1	
85	Phenotype and prognostic correlations of the converter region mutations affecting the myosin heavy chain. *Heart*, **2015**, 101, 1047-53	5.1	34
84	NKX2-5 mutations in an inbred consanguineous population: genetic and phenotypic diversity. *Scientific Reports*, **2015**, 5, 8848	4.9	32
83	De novo mutations in congenital heart disease with neurodevelopmental and other congenital anomalies. *Science*, **2015**, 350, 1262-6	33.3	406

82	Diltiazem treatment for pre-clinical hypertrophic cardiomyopathy sarcomere mutation carriers: a pilot randomized trial to modify disease expression. *JACC: Heart Failure*, **2015**, 3, 180-8	7.9	105
81	Results of clinical genetic testing of 2,912 probands with hypertrophic cardiomyopathy: expanded panels offer limited additional sensitivity. *Genetics in Medicine*, **2015**, 17, 880-8	8.1	236
80	Genetic Pathways in Congenital Heart Development. *FASEB Journal*, **2015**, 29, 215.3	0.9	
79	Increased frequency of de novo copy number variants in congenital heart disease by integrative analysis of single nucleotide polymorphism array and exome sequence data. *Circulation Research*, **2014**, 115, 884-896	15.7	158
78	126 Advanced Assessment of Cardiac Morphology and Prediction of Gene Carriage by CMR in Hypertrophic Cardiomyopathy - The HCMNET/UCL Collaboration. *Heart*, **2014**, 100, A72-A73	5.1	1
77	Biobank participantsR preferences for disclosure of genetic research results: perspectives from the OurGenes, OurHealth, OurCommunity project. *Mayo Clinic Proceedings*, **2014**, 89, 738-46	6.4	42
76	Alpha blockade potentiates CPVT therapy in calsequestrin-mutant mice. *Heart Rhythm*, **2014**, 11, 1471-9	6.7	16
75	Nationwide study on hypertrophic cardiomyopathy in Iceland: evidence of a MYBPC3 founder mutation. *Circulation*, **2014**, 130, 1158-67	16.7	44
74	Tbx5 is required for avian and Mammalian epicardial formation and coronary vasculogenesis. *Circulation Research*, **2014**, 115, 834-44	15.7	23
73	UBQLN2 mutation causing heterogeneous X-linked dominant neurodegeneration. *Annals of Neurology*, **2014**, 75, 793-798	9.4	38
72	Targeted and genome-wide sequencing reveal single nucleotide variations impacting specificity of Cas9 in human stem cells. *Nature Communications*, **2014**, 5, 5507	17.4	106
71	Myosin heavy chain variant Val606Met causes very mild hypertrophic cardiomyopathy in mice, but exacerbates HCM phenotypes in mice carrying other HCM mutations. *Circulation Research*, **2014**, 115, 227-37	15.7	29
70	5R RNA-Seq identifies Fhl1 as a genetic modifier in cardiomyopathy. *Journal of Clinical Investigation*, **2014**, 124, 1364-70	15.9	44
69	Genetics of congenital heart disease: the glass half empty. *Circulation Research*, **2013**, 112, 707-20	15.7	369
68	Effects of losartan on left ventricular hypertrophy and fibrosis in patients with nonobstructive hypertrophic cardiomyopathy. *JACC: Heart Failure*, **2013**, 1, 480-7	7.9	75
67	Elevated rates of force development and MgATP binding in F764L and S532P myosin mutations causing dilated cardiomyopathy. *Journal of Molecular and Cellular Cardiology*, **2013**, 57, 23-31	5.8	15
66	De novo mutations in histone-modifying genes in congenital heart disease. *Nature*, **2013**, 498, 220-3	50.4	591
65	HOXA2 haploinsufficiency in dominant bilateral microtia and hearing loss. *Human Mutation*, **2013**, 34, 1347-51	4.7	30

64	The Congenital Heart Disease Genetic Network Study: rationale, design, and early results. *Circulation Research*, **2013**, 112, 698-706	15.7	104
63	Subtle abnormalities in contractile function are an early manifestation of sarcomere mutations in dilated cardiomyopathy. *Circulation: Cardiovascular Genetics*, **2012**, 5, 503-10		56
62	Truncations of titin causing dilated cardiomyopathy. *New England Journal of Medicine*, **2012**, 366, 619-28	59.2	874
61	Hypertrophic cardiomyopathy: translating cellular cross talk into therapeutics. *Journal of Cell Biology*, **2012**, 199, 417-21	7.3	34
60	2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Journal of Thoracic and Cardiovascular Surgery*, **2011**, 142, 1303-38	1.5	59
59	2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Circulation*, **2011**, 124, 2761-96	16.7	587
58	Identifying sarcomere gene mutations in hypertrophic cardiomyopathy: a personal history. *Circulation Research*, **2011**, 108, 743-50	15.7	167
57	Activation of multiple signaling pathways causes developmental defects in mice with a Noonan syndrome-associated Sos1 mutation. *Journal of Clinical Investigation*, **2010**, 120, 4353-65	15.9	79
56	Short communication: the cardiac myosin binding protein C Arg502Trp mutation: a common cause of hypertrophic cardiomyopathy. *Circulation Research*, **2010**, 106, 1549-52	15.7	56
55	Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy. *New England Journal of Medicine*, **2010**, 363, 552-63	59.2	452
54	Genetics of hypertrophic cardiomyopathy. *Current Opinion in Cardiology*, **2010**, 25, 205-9	2.1	90
53	Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires Tgf- *Journal of Clinical Investigation*, **2010**, 120, 3520-9	15.9	301
52	A classic twin study of external ear malformations, including microtia. *New England Journal of Medicine*, **2009**, 361, 1216-8	59.2	23
51	De novo copy number variants identify new genes and loci in isolated sporadic tetralogy of Fallot. *Nature Genetics*, **2009**, 41, 931-5	36.3	325
50	Lamin A/C haploinsufficiency causes dilated cardiomyopathy and apoptosis-triggered cardiac conduction system disease. *Journal of Molecular and Cellular Cardiology*, **2008**, 44, 293-303	5.8	122
49	Sarcomere Protein Gene Mutations and Inherited Heart Disease: A Cardiac Myosin Heavy Chain Mutation Causing Endocardial Fibroelastosis and Heart Failure. *Novartis Foundation Symposium*, **2008**, 176-195		10
48	Polony multiplex analysis of gene expression (PMAGE) in mouse hypertrophic cardiomyopathy. *Science*, **2007**, 316, 1481-4	33.3	155
47	Cardiac myosin missense mutations cause dilated cardiomyopathy in mouse models and depress molecular motor function. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 14525-30	11.5	76

46	Gene mutations in apical hypertrophic cardiomyopathy. *Circulation*, **2005**, 112, 2805-11	16.7	165
45	Differential cross-bridge kinetics of FHC myosin mutations R403Q and R453C in heterozygous mouse myocardium. *American Journal of Physiology - Heart and Circulatory Physiology*, **2004**, 287, H91-9	5.2	61
44	American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. *Journal of the American College of Cardiology*, **2003**,	15.1	1187
43	Dilated cardiomyopathy and heart failure caused by a mutation in phospholamban. *Science*, **2003**, 299, 1410-3	33.3	492
42	Assessment of diastolic function with Doppler tissue imaging to predict genotype in preclinical hypertrophic cardiomyopathy. *Circulation*, **2002**, 105, 2992-7	16.7	298
41	Sarcomere protein gene mutations in hypertrophic cardiomyopathy of the elderly. *Circulation*, **2002** , 105, 446-51	16.7	269
40	Genetic causes of inherited cardiac hypertrophy: Robert L. Frye Lecture. *Mayo Clinic Proceedings*, **2002**, 77, 1315-9	6.4	12
39	The L-type calcium channel inhibitor diltiazem prevents cardiomyopathy in a mouse model. *Journal of Clinical Investigation*, **2002**, 109, 1013-20	15.9	106
38	The L-type calcium channel inhibitor diltiazem prevents cardiomyopathy in a mouse model. *Journal of Clinical Investigation*, **2002**, 109, 1013-1020	15.9	199
37	Introduction of plasmid DNA into cells. *Current Protocols in Neuroscience*, **2001**, Appendix 1, Appendix 1L	2.7	
36	The genetic basis for cardiomyopathy: from mutation identification to mechanistic paradigms. *Cell*, **2001**, 104, 557-67	56.2	846
35	A murine model of Holt-Oram syndrome defines roles of the T-box transcription factor Tbx5 in cardiogenesis and disease. *Cell*, **2001**, 106, 709-21	56.2	833
34	Introduction of plasmid DNA into cells. *Current Protocols in Protein Science*, **2001**, Appendix 4, 4D	3.1	6
33	Homozygous mutation in cardiac troponin T: implications for hypertrophic cardiomyopathy. *Circulation*, **2000**, 102, 1950-5	16.7	123
32	Mutations in sarcomere protein genes as a cause of dilated cardiomyopathy. *New England Journal of Medicine*, **2000**, 343, 1688-96	59.2	550
31	Genetics of Cardiovascular Disease. *Circulation*, **2000**, 102,	16.7	3
30	An alpha-cardiac myosin heavy chain gene mutation impairs contraction and relaxation function of cardiac myocytes. *American Journal of Physiology - Heart and Circulatory Physiology*, **1999**, 276, H1780-7	5.2	36
29	Electrophysiologic characteristics of accessory atrioventricular connections in an inherited form of Wolff-Parkinson-White syndrome. *Journal of Cardiovascular Electrophysiology*, **1999**, 10, 629-35	2.7	41

28	QTL influencing autoimmune diabetes and encephalomyelitis map to a 0.15-cM region containing Il2. *Nature Genetics*, **1999**, 21, 158-60	36.3	116
27	Regulation of chamber-specific gene expression in the developing heart by Irx4. *Science*, **1999**, 283, 1161-4	33.3	199
26	Mutations in the cardiac transcription factor NKX2.5 affect diverse cardiac developmental pathways. *Journal of Clinical Investigation*, **1999**, 104, 1567-73	15.9	468
25	Altered cardiac excitation-contraction coupling in mutant mice with familial hypertrophic cardiomyopathy. *Journal of Clinical Investigation*, **1999**, 103, 661-6	15.9	46
24	Dilated cardiomyopathy in homozygous myosin-binding protein-C mutant mice. *Journal of Clinical Investigation*, **1999**, 104, 1235-44	15.9	179
23	Familial hypertrophic cardiomyopathy mice display gender differences in electrophysiological abnormalities. *Journal of Interventional Cardiac Electrophysiology*, **1998**, 2, 7-14	2.4	37
22	Mutations in a novel cochlear gene cause DFNA9, a human nonsyndromic deafness with vestibular dysfunction. *Nature Genetics*, **1998**, 20, 299-303	36.3	286
21	Mutations in human TBX5 [corrected] cause limb and cardiac malformation in Holt-Oram syndrome. *Nature Genetics*, **1997**, 15, 30-5	36.3	887
20	Mutations in human TBX3 alter limb, apocrine and genital development in ulnar-mammary syndrome. *Nature Genetics*, **1997**, 16, 311-5	36.3	456
19	Amyloid-beta proteins activate Ca(2+)-permeable channels through calcium-sensing receptors. *Journal of Neuroscience Research*, **1997**, 47, 547-54	4.4	93
18	Targeted ablation of the murine alpha-tropomyosin gene. *Circulation Research*, **1997**, 81, 1005-10	15.7	81
17	beta-Arrestin1 knockout mice appear normal but demonstrate altered cardiac responses to beta-adrenergic stimulation. *Circulation Research*, **1997**, 81, 1021-6	15.7	155
16	A human MSX1 homeodomain missense mutation causes selective tooth agenesis. *Nature Genetics*, **1996**, 13, 417-21	36.3	551
15	Missense mutation in the pore region of HERG causes familial long QT syndrome. *Circulation*, **1996**, 93, 1791-5	16.7	55
14	A mouse model of human familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. *Nature Genetics*, **1995**, 11, 389-94	36.3	519
13	Mutations in the cardiac myosin binding protein-C gene on chromosome 11 cause familial hypertrophic cardiomyopathy. *Nature Genetics*, **1995**, 11, 434-7	36.3	482
12	A de novo mutation in alpha-tropomyosin that causes hypertrophic cardiomyopathy. *Circulation*, **1995**, 91, 2302-5	16.7	44
11	A gene for hereditary haemorrhagic telangiectasia maps to chromosome 9q3. *Nature Genetics*, **1994**, 6, 205-9	36.3	174

10	A complex bilateral polysyndactyly disease locus maps to chromosome 7q36. *Nature Genetics*, **1994**, 6, 282-6	36.3	79
9	Autosomal dominant hypocalcaemia caused by a Ca(2+)-sensing receptor gene mutation. *Nature Genetics*, **1994**, 8, 303-7	36.3	513
8	Homozygosity mapping of the gene for alkaptonuria to chromosome 3q2. *Nature Genetics*, **1993**, 5, 201-4	36.3	110
7	The gene responsible for familial hypocalciuric hypercalcemia maps to chromosome 3q in four unrelated families. *Nature Genetics*, **1992**, 1, 295-300	36.3	135
6	A molecular basis for familial hypertrophic cardiomyopathy: a beta cardiac myosin heavy chain gene missense mutation. *Cell*, **1990**, 62, 999-1006	56.2	1042
5	Mapping a gene for familial hypertrophic cardiomyopathy to chromosome 14q1. *New England Journal of Medicine*, **1989**, 321, 1372-8	59.2	415
4	Whole Genome De Novo Variant Identification with FreeBayes and Neural Network Approaches		3
3	Cells and gene expression programs in the adult human heart		9
2	MYBPC3 Mutations cause Hypertrophic Cardiomyopathy by Dysregulating Myosin: Implications for Therapy		1
1	Early post-zygotic mutations contribute to congenital heart disease		2